drugset / Trial / NCT06788197
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to evaluate the efficacy and safety of SHR-A1811 and Fulvestrant in Combination with or without HS-10352 in locally advanced or metastatic breast cancer patients. Subjects will receive SHR-A1811 and Fulvestrant in Combination with or without HS-10352.
Timeline
- Start
- 2025-03
- Primary completion
- 2028-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | HS-10352 | Small molecule | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |